CEO Dr Leearne Hinch said, “This core patent family provides intellectual property protection in the US and Europe for our BARD1-Ovarian and BARD1-Breast cancer tests in development for early detection of ovarian and breast cancers.”

Anatara recently said it was finalising discussions with third parties to progress challenge trials of its animal health assets to address barriers to partnering.

The Coalition for Epidemic Preparedness Innovations has released the findings of a survey designed to determine the available global manufacturing capacity for any COVID-19 vaccine.

Janssen has teamed up with Monash University for a research and development program to advance the development of inhaled oxytocin for the prevention of postpartum hemorrhage in developing countries.

US company Novavax has reported positive results from the Australian-based phase one trial of its investigative COVID-19 vaccine.

A leading group of contract research organisations under the auspices of ARCS Australia are calling on the federal government to improve policies and processes around the national coordination of clinical trials in Australia.

Australian company Adherium (ASX: ADR) has announced the appointment of Geoff Feakes as its chief technology officer (CTO).

Australian company Hatchtech has announced commercialisation partner, Dr Reddy’s Laboratories, has secured US FDA approval of XEGLYZE (abametapir) Lotion 0.74% for the topical treatment of head lice in patients six months of age and older.

Register by Wednesday 5 August to save up to $200 on registration to AusBiotech + Invest 2020 –Australia’s biggest week in biotech that in October will feature the event you know and trust, with new opportunities for global delegates and speakers, and a new level of global insight and perspective.